However, we observed that lipid-droplets in LO2 and HepG2 cells were significantly reduced in PGPIPN 1, 2 and 3 (Figure 1A3, 1A4, 1A5, 1C3, 1C4 and 1C5) groups, PGPIPN treatment took effect in a dose-dependent manner (Figure 1B and 1D)
Why Injections Offer Higher BPC-157 Bioavailability Because it bypasses digestion entirely, it bypasses digestion and may offer higher systemic availability
Our B12 Injections in Fort Myers, FL, deliver a highly bioavailable form (hydroxycobalamin) directly into the bloodstream for rapid absorption and sustained benefits
PlexusDx patients receive detailed storage instructions with every shipment to protect their compounded medications
FOXO4-DRI Key Research Facts Full name: FOXO4 D-Retro-Inverso peptide (FOXO4-DRI) Classification: Cell-penetrating senolytic peptide FOXO4/p53 protein-protein interaction inhibitor Design: D-retro-inverso isoform of FOXO4s p53-binding domain reversed sequence with all D-amino acids Binding target: p53 transactivation domain 2 (TAD2) displaces FOXO4 from the FOXO4-p53 complex Mechanism: FOXO4-DRI binds p53 TAD2 p53 nuclear exclusion p53 mitochondrial translocation BAX activation caspase-3 cleavage senescent cell-selective apoptosis Selectivity basis: FOXO4 is upregulated in senescent cells but expressed at low levels in most non-senescent adult cells selectivity is mechanistically conferred D-amino acid advantage: Proteolytic stability resistant to intracellular peptidases that would rapidly degrade equivalent L-amino acid sequences Structural characterisation: NMR structural models of FOXO4-DRI/p53TAD2 complex resolved (Nature Communications, 2025) confirms disordered-to-ordered transition upon binding Research cell types studied: IMR90 fibroblasts, TM3 Leydig cells, endothelial cells, chondrocytes, keloid fibroblasts, HCT116 cancer cells In vitro working concentration: 25 M used in multiple published studies for senescent cell apoptosis induction What Does FOXO4-DRI Do in Research
